ArticleClinical and experimental medicine2026
PRKD1/EIF5A/β-catenin axis inhibits tumorigenesis and metastasis in non-small-cell lung cancer.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PRKD1 is downregulated in non-small-cell lung cancer (NSCLC). Whether and how PRKD1 regulates tumorigenesis and metastasis is previously unknown. Here, we report that PRKD1 negatively regulates β-catenin protein abundance. PRKD1 promotes ubiquitination and degradation of EIF5A. EIF5A upregulates β-catenin and activates the Wnt signaling pathway. Thus, the PRKD1/EIF5A/β-catenin axis modulates the Wnt signaling pathway in NSCLC. Functionally, PRKD1 inhibits cell proliferation and metastasis both in vitro and in vivo. PRKD1 is downregulated and EIF5A is upregulated in NSCLC. Lower PRKD1 and higher EIF5A predict a worse patient survival. Our study suggests that the PRKD1/EIF5A/β-catenin axis is involved in the carcinogenesis of NSCLC and may serve as a new therapeutic target for NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.